Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMVT Immunovant	$15.46 -1.7%	$16.55	$12.72 ▼ $34.47	$2.64B	0.66	1.28 million shs	646,798 shs
KYMR Kymera Therapeutics	$40.62 -0.6%	$45.11	$19.44 ▼ $53.27	$2.65B	2.18	537,031 shs	840,550 shs
RARE Ultragenyx Pharmaceutical	$27.54 -1.0%	$33.32	$25.81 ▼ $60.37	$2.65B	0.25	2.61 million shs	1.53 million shs
STOK Stoke Therapeutics	$13.10 -1.1%	$12.05	$5.35 ▼ $16.15	$715.26M	1.15	767,183 shs	385,342 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMVT Immunovant	0.00%	-1.59%	-14.73%	+6.25%	-47.07%
KYMR Kymera Therapeutics	0.00%	-5.45%	-8.68%	+26.27%	-1.98%
RARE Ultragenyx Pharmaceutical	0.00%	-3.16%	-6.68%	-23.69%	-44.95%
STOK Stoke Therapeutics	0.00%	+1.47%	+10.46%	+35.61%	-9.15%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMVT Immunovant	1.5152 of 5 stars	3.4	0.0	0.0	2.9	1.7	0.0
KYMR Kymera Therapeutics	3.3303 of 5 stars	4.6	3.0	0.0	2.2	2.5	0.0
RARE Ultragenyx Pharmaceutical	4.3877 of 5 stars	4.5	1.0	3.8	2.9	2.5	0.6
STOK Stoke Therapeutics	3.9525 of 5 stars	3.6	1.0	4.8	1.9	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMVT Immunovant	2.80	Moderate Buy	$35.33	128.55% Upside
KYMR Kymera Therapeutics	3.10	Buy	$59.11	45.52% Upside
RARE Ultragenyx Pharmaceutical	2.92	Moderate Buy	$81.50	195.93% Upside
STOK Stoke Therapeutics	3.29	Buy	$25.80	96.95% Upside

Current Analyst Ratings Breakdown

Latest STOK, KYMR, RARE, and IMVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	RARE Ultragenyx Pharmaceutical	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$136.00 ➝ $128.00
8/6/2025	RARE Ultragenyx Pharmaceutical	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$112.00 ➝ $105.00
7/30/2025	KYMR Kymera Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$60.00
7/28/2025	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$17.00 ➝ $18.00
7/28/2025	RARE Ultragenyx Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$80.00
7/18/2025	STOK Stoke Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
7/15/2025	KYMR Kymera Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/14/2025	RARE Ultragenyx Pharmaceutical	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$35.00 ➝ $34.00
7/14/2025	RARE Ultragenyx Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$65.00 ➝ $55.00
7/10/2025	IMVT Immunovant	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$18.00
7/10/2025	RARE Ultragenyx Pharmaceutical	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$88.00 ➝ $65.00

(Data available from 8/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.16 per share	N/A
KYMR Kymera Therapeutics	$47.07M	56.20	N/A	N/A	$12.90 per share	3.15
RARE Ultragenyx Pharmaceutical	$560.23M	4.74	N/A	N/A	$2.76 per share	9.98
STOK Stoke Therapeutics	$36.56M	19.56	N/A	N/A	$4.32 per share	3.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMVT Immunovant	-$413.84M	-$2.74	N/A	N/A	N/A	N/A	-80.60%	-71.89%	8/12/2025 (Estimated)
KYMR Kymera Therapeutics	-$223.86M	-$3.10	N/A	N/A	N/A	-409.07%	-30.11%	-25.65%	8/11/2025 (Estimated)
RARE Ultragenyx Pharmaceutical	-$569.18M	-$5.53	N/A	N/A	N/A	-87.34%	-237.48%	-37.66%	N/A
STOK Stoke Therapeutics	-$88.98M	$0.79	16.58	N/A	N/A	26.33%	19.08%	15.72%	8/12/2025 (Estimated)

Latest STOK, KYMR, RARE, and IMVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q1 2026	IMVT Immunovant	-$0.69	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	STOK Stoke Therapeutics	-$0.0905	N/A	N/A	N/A	$31.51 million	N/A
8/11/2025	Q2 2025	KYMR Kymera Therapeutics	-$0.84	N/A	N/A	N/A	$17.37 million	N/A
8/5/2025	Q2 2025	RARE Ultragenyx Pharmaceutical	-$1.27	-$1.17	+$0.10	-$1.17	$161.37 million	$166.50 million
5/29/2025	Q4 2025	IMVT Immunovant	-$0.72	-$0.64	+$0.08	-$0.64	N/A	$0.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMVT Immunovant	N/A	11.16	11.16
KYMR Kymera Therapeutics	N/A	8.49	8.49
RARE Ultragenyx Pharmaceutical	N/A	2.45	2.30
STOK Stoke Therapeutics	N/A	8.41	8.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMVT Immunovant	47.08%
KYMR Kymera Therapeutics	N/A
RARE Ultragenyx Pharmaceutical	97.67%
STOK Stoke Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
IMVT Immunovant	1.80%
KYMR Kymera Therapeutics	16.01%
RARE Ultragenyx Pharmaceutical	5.50%
STOK Stoke Therapeutics	9.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMVT Immunovant	120	171.07 million	167.99 million	Optionable
KYMR Kymera Therapeutics	170	65.12 million	54.69 million	Optionable
RARE Ultragenyx Pharmaceutical	1,294	96.37 million	91.07 million	Optionable
STOK Stoke Therapeutics	100	54.60 million	49.41 million	Optionable

STOK, KYMR, RARE, and IMVT Headlines

Recent News About These Companies

Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

August 6, 2025 | businesswire.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Insider Barry Ticho Sells 4,504 Shares

August 6, 2025 | marketbeat.com

Stoke Therapeutics (STOK) Expected to Announce Quarterly Earnings on Wednesday

August 5, 2025 | americanbankingnews.com

The Oligonucleotide Therapeutics Society Announces the 21st Annual Meeting in Budapest, Hungary

August 1, 2025 | msn.com

Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for

July 30, 2025 | zacks.com

Stoke Therapeutics (STOK) to Release Quarterly Earnings on Wednesday

July 30, 2025 | marketbeat.com

28,600 Shares in Stoke Therapeutics, Inc. (NASDAQ:STOK) Bought by Dauntless Investment Group LLC

July 29, 2025 | marketbeat.com

Stoke Therapeutics Inc. Stock Grades | STOK | Barron's

July 28, 2025 | barrons.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Rating of "Buy" by Analysts

July 25, 2025 | marketbeat.com

Stoke Therapeutics (NASDAQ:STOK) Shares Up 18.1% - Here's Why

July 22, 2025 | marketbeat.com

Kennondale Capital Management LLC Acquires Shares of 42,100 Stoke Therapeutics, Inc. (NASDAQ:STOK)

July 22, 2025 | marketbeat.com

Stoke Therapeutics (NASDAQ:STOK) Trading Down 4.3% - Here's Why

July 21, 2025 | marketbeat.com

Jefferies Initiates Coverage of Stoke Therapeutics (STOK) with Buy Recommendation

July 19, 2025 | msn.com

Jefferies starts Stoke at Buy, sees $1 bln+ opportunity in rare epilepsy drug

July 19, 2025 | finance.yahoo.com

Stoke Therapeutics (NASDAQ:STOK) Shares Gap Up - What's Next?

July 18, 2025 | marketbeat.com

Stoke Therapeutics (NASDAQ:STOK) Now Covered by Analysts at Jefferies Financial Group

July 18, 2025 | marketbeat.com

Epilepsy Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

July 15, 2025 | theglobeandmail.com

Stoke Therapeutics (NASDAQ:STOK) investors are sitting on a loss of 58% if they invested five years ago

July 15, 2025 | finance.yahoo.com

The charming Stoke-on-Trent four-bed family home that's 'ready to be lived in'

July 13, 2025 | msn.com

New Royal Stoke technology cuts hospital stays by over a day

July 13, 2025 | msn.com

Stoke City Boss Delighted To Finally Get Signing Over The Line

July 13, 2025 | therealefl.co.ukT

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why the American Eagle Stock Rally Isn't Just Speculation
By Gabriel Osorio-Mazilli | July 28, 2025
View Why the American Eagle Stock Rally Isn't Just Speculation
3 Short Squeeze Candidates With Big Catalysts on the Horizon
By Dan Schmidt | July 25, 2025
View 3 Short Squeeze Candidates With Big Catalysts on the Horizon
These 3 Rare Earth Stocks Are Surging Alongside MP Materials
By Leo Miller | July 19, 2025
View These 3 Rare Earth Stocks Are Surging Alongside MP Materials
NVIDIA: A Major Indicator Just Flashed Sell, But Should You?
By Sam Quirke | July 30, 2025
View NVIDIA: A Major Indicator Just Flashed Sell, But Should You?
MP Materials Stock Booms on New Government Positioning
By Gabriel Osorio-Mazilli | July 14, 2025
View MP Materials Stock Booms on New Government Positioning

STOK, KYMR, RARE, and IMVT Company Descriptions

Immunovant NASDAQ:IMVT

$15.46 -0.27 (-1.72%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$15.30 -0.16 (-1.01%)

As of 04:30 AM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Kymera Therapeutics NASDAQ:KYMR

$40.62 -0.23 (-0.56%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$40.62 +0.01 (+0.01%)

As of 08/8/2025 04:14 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Ultragenyx Pharmaceutical NASDAQ:RARE

$27.54 -0.29 (-1.04%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$27.56 +0.02 (+0.05%)

As of 08/8/2025 05:21 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Stoke Therapeutics NASDAQ:STOK

$13.10 -0.15 (-1.13%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$12.92 -0.17 (-1.34%)

As of 08/8/2025 07:55 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time